CAMBRIDGE, Mass.–(BUSINESS WIRE)– Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that the results of analytical and biophysical assays conducted as part of the company’s chemistry, manufacturing, and controls (CMC) development process for REN-001 will be featured in an upcoming poster presentation at the 29^th European Society of Gene & Cell Therapy (ESGCT) Congress. The congress is taking place from October 11 – 14, 2022, at the Edinburgh International Conference Centre in Edinburgh, Scotland.